

# Prevalence and antimicrobial susceptibility of respiratory pathogens in patients with cystic fibrosis

## Authors

Vilma Almeida Paixão<sup>1,2</sup>

Tânia Fraga Barros<sup>2</sup>

Clélia Maria C Mota<sup>1,2</sup>

Tamy Fagundes Moreira<sup>2</sup>

Maria Angélica Santana<sup>1</sup>

Joice Neves Reis<sup>2</sup>

<sup>1</sup>Secretary of Health of Bahia State, Brazil; Hospital Especializado Otávio Mangabeira, Bahia, Brazil.

<sup>2</sup>Postgraduation in Microbiology; Department of Clinical and Toxicological Analysis, Pharmacy School, Universidade Federal da Bahia, Brazil.

## ABSTRACT

Respiratory infection is very common in patients suffering from cystic fibrosis (CF). However, the antimicrobial resistance rate of isolates from CF patients is not often documented. In this study, 279 respiratory specimens of 146 patients were prospectively collected from July to December 2006. Microbiological cultures and antimicrobial susceptibility tests of the most frequently isolated bacteria were performed. Sputum and oropharyngeal swabs were processed for culture. During the study period, 50% of the patients harbored *Staphylococcus aureus*, 35% *Pseudomonas aeruginosa*, 4.7% *Haemophilus influenzae*. Methicillin resistant *S. aureus* (MRSA) were detected in 8 (6%) patients; ESBL and MBL-producing *P. aeruginosa* were not identified in these patients. The detection of MRSA in CF patients confirms that antimicrobial resistance patterns should be always kept under surveillance. Moreover, hygiene regulations in CF clinics should prevent a further spread of resistant bacterial strains.

**Keywords:** cystic fibrosis, antimicrobial resistance, *Pseudomonas aeruginosa*, *Staphylococcus aureus*.

[Braz J Infect Dis 2010;14(4):406-409]©Elsevier Editora Ltda.

## BACKGROUND

The main feature of cystic fibrosis (CF) is chronic respiratory infection, which may start very early in the life of these patients. Since the early description of CF, pulmonary infection has been recognized as playing the greatest role in morbidity and mortality leading to premature death in 90% of patients.<sup>1</sup> Impairment of the muco-ciliary transport and thus the cleaning function of the upper airway predisposes for bacterial colonization and chronic infections by *Staphylococcus aureus* and *Pseudomonas aeruginosa*.<sup>1,2</sup> Subsequently, the microbiology of CF becomes more complex when other non-fermenting Gram-negative organisms, such as members of the *Burkholderia cepacia*-complex ensue and *Pseudomonas aeruginosa* switch to the mucoid phenotype, which is more difficult to eradicate.<sup>3,4</sup>

Increase in multidrug-resistance in Gram-negative pathogens such as *Pseudomonas aeruginosa* and *Burkholderia cepacia* complex makes the therapeutic management of CF patients more complex since the therapeutic options are very limited.<sup>5</sup> Thus, careful isola-

tion and identification, and accurate studies of susceptibility to antibiotics are critical for predicting the spread of strains, improving therapeutic measures and facilitating our understanding of the epidemiology of these pathogens. The aim of this study was to determine the prevalence of pathogens isolated from respiratory samples of CF patients receiving care at the Referral Cystic Fibrosis Center of Bahia, and to evaluate the spectrum of antimicrobial-resistance of these organisms.

## METHODS

### Patients and samples

A clinical laboratory study including 146 patients attending regularly the Referral Center for Cystic Fibrosis of Bahia, *Hospital Otávio Mangabeira*, between July and December 2006 was conducted. The diagnosis of CF was confirmed according to the criteria of the Cystic Fibrosis Foundation.<sup>6</sup> Spontaneous and induced sputum samples and oropharyngeal swabs were obtained for each patient during periods of clinical stability at regular clinical

Submitted on: 07/28/2009

Approved on: 11/17/2009

### Correspondence to:

Vilma Almeida Paixão  
Rua das Gaivotas, no. 128  
BL- C, Apto 1503, Imbuí,  
Salvador –  
Bahia – Brazil  
CEP: 41720-070  
Phone: +55-71-32312078  
Phone(Fax):  
+55-71-32372255  
E-mail: vvilmapaixao@  
gmail.com

We declare no conflict  
of interest.

and physiotherapy attendance was performed every three months. Patients with history of antibiotic therapy in the last 90 days were excluded.

### Processing of sputum samples and culture of organisms

Spontaneous sputum samples obtained from all patients involved during the study period were mixed with equal volumes of 1% dithiothreitol (Merck, Germany) before incubation at 37 °C for 30 min. When it was not possible to obtain spontaneous sputum samples, an oropharyngeal swab was used as a sample. All specimens were examined microscopically and cultured in agar blood, agar chocolate, MacConkey agar, Mannitol Salt Agar, and Burkholderia cepacea agar (BCSA) incubated for a period of 18 to 48 hours at 36 °C, followed by room temperature incubation for up to 72 hours. All isolates obtained from the samples were identified by the autoSCAN-4 (Dade Behring, Inc., West Sacramento, CA, USA). Preparation of suspensions, inoculations, incubation times, temperatures, and interpretation of reactions were performed according to the manufacturer's instructions. Additional biochemical tests for bacterial identification were performed whenever necessary.

### Antimicrobial susceptibility testing

Susceptibility testing of all bacterial strains was carried out through broth microdilution assay using an automated autoSCAN-4 system (Dade Behring, Inc., West Sacramento, CA, USA) and by disk diffusion technique according to the CLSI criteria.<sup>7</sup>

### Statistical analysis

Epi-Info version 3.2 software (Centers for Disease Control and Prevention, US) was used for data entry and

descriptive statistical analysis. Categorical and continuous variables are presented as number and proportion, and median and range, respectively.

### Ethical considerations

The study was approved by the Ethical Committee from the SESAB (Secretária de Saúde do Estado da Bahia). Written informed consent and verbal assent were obtained from each patient or children's parent or guardian and from all study participants, respectively.

## RESULTS

During the study period, 146 patients (75 males, 71 females; mean age 14.5 years, ranging from 4 months to 77 years) were referred to the Referral Center for Cystic Fibrosis of Bahia, *Hospital Otavio Mangabeira*. A total of 369 biological samples (337 sputum and 32 oropharynx swabs) were analyzed and 279 bacterial strains were isolated and identified. The most frequent pathogens were *S. aureus* (35%) and *P. aeruginosa* (21%), with the highest rate of colonization observed in patients in the age group of 6 - 10 years and above 17 years old, respectively (Table 1).

In 35.6% of the samples analyzed, more than one microorganism were isolated, being the most frequent combination *S. aureus* and *P. aeruginosa*, found in 10% (15 of 146) of the patients, while 85% (125 of 146) of the patients had only one pathogen identified in all cultured samples. During the study period only one patient, a 13-year old boy, was chronically infected by *Burkholderia cepacia complex*, with positive cultures in all four samples collected monthly. This pathogen exhibited the mucoid phenotype and was highly susceptible to piperacillin, imipenem, aminoglycosides, and ciprofloxacin.

**Table 1. Prevalence of pathogens identified from respiratory specimens in patients with cystic fibrosis, classified by age group (n = 146)**

Age (years)	Nº (%) of patients	<i>S. aureus</i>	Non-mucoid <i>P. aeruginosa</i>	Mucoid <i>P. aeruginosa</i>	<i>K. pneumoniae</i>	<i>H. influenzae</i>	<i>Acinetobacter</i> spp	<i>Alcaligenes</i> spp	<i>Burkholderia</i> sp	<i>S. maltophilia</i>	Others gram-negative
≤ 1	17 (12%)	7	1	1	5	2	0	0	0	1	6
2 - 5	28 (19%)	14	3	3	2	2	0	1	0	1	12
6 - 10	41 (28%)	29	0	5	2	1	1	0	0	0	15
11 - 17	28 (19%)	11	5	2	1	0	1	0	1	0	6
≥ 17	32 (22%)	12	8	6	2	2	2	2	0	1	10
Total	146	73	34	17	12	7	4	3	1	3	49

**Table 2. Rate of susceptibility (%) of mucoid and non-mucoid *Pseudomonas aeruginosa* isolates against different antimicrobial agents**

Antimicrobial agents	Rate of susceptibility (%)	
	Non-Mucoid <i>P. aeruginosa</i> (42)	Mucoid <i>P. aeruginosa</i> (17)
Amikacin	83	75
Aztreonam	83	75
Ceftazidime	79	75
Ciprofloxacin	79	88
Gentamicin	55	56
Imipenem	100	88
Meropenem	100	100
Piperacillin	88	94
Tobramycin	88	81

**Table 3. Rate of susceptibility (%) of *S. aureus* isolates against different antimicrobial agents (n = 99)**

Antimicrobial agents	Rate of susceptibility (%)
Amoxicillin/clavulanate	94
Cefazoline	94
Ceftriaxone	94
Ciprofloxacin	90
Clindamycin	90
Cotrimoxazole	86
Erythromycin	79
Gentamicin	96
Rifampicin	96
Linezolid	100
Vancomycin	100

Susceptibility studies of *P. aeruginosa* over the study period are summarized in Table 2. In this population, non-mucoid *P. aeruginosa* isolates exhibited a much higher antimicrobial susceptibility than the mucoid strains, being fully susceptible to imipenem and meropenem. Both phenotypes were mainly gentamicin-resistant (45% and 44%), respectively.

Methicillin resistant *Staphylococcus aureus* (MRSA) was isolated from 6% of the patients. Among these, MRSA isolates showed no resistance against vancomycin, linezolid and rifampicin. Constitutive clindamycin resistance was detected in 10% of the isolates, and inducible clindamycin resistance was not identified in this study population. Rates of susceptibility of *S. aureus* are presented in Table 3.

## DISCUSSION

Colonization by pathogenic microorganisms in the respiratory tract of patients with CF occurs at young age and represents a serious health problem because it is considered a major cause of morbidity and mortality.<sup>1</sup> As reported in previous studies on the prevalence and antimicrobial susceptibility of bacterial isolates from CF patients in USA, Germany, and South America, we found that *Staphylococcus aureus* and *Pseudomonas aeruginosa* are the most frequent pathogens in this population.<sup>8-13</sup> The prevalence of *S. aureus* was highest (70.7%) among children of 6 to 10 years of age. In older age group (11-17 and > 17 years of age), the prevalence of *S. aureus* isolates declined as the prevalence of *P. aeruginosa* increased. However, *S. aureus* remained the most frequently isolated bacteria, regardless of patient age group.

Methicillin resistant *S. aureus* (MRSA) was isolated from eight patients (6%) during our study, similar to the 5% reported in Germany.<sup>9</sup> The rate of MRSA in comparison with the total amount of *S. aureus* isolates was 10%. In contrast, a rate of methicillin resistance in CF patients as high as 18.8% was reported in the United States;<sup>13,14</sup> 25.9% in Argentina;<sup>11</sup> and 18% in Spain. Presumably, the differences in the MRSA rates in CF-patients correlate with the general nosocomial and community prevalence of MRSA of each country.

*Pseudomonas aeruginosa* producing metallo- $\beta$ -lactamase (MBLs) was first reported in Japan in 1991,<sup>15</sup> and since then it has been described as associated with outbreaks of hospital-acquired infection in several countries.<sup>16-18</sup> The first report of MBL-producing *P. aeruginosa* in CF patients was from Germany (5%).<sup>9</sup> In this study sample, we did not identify any MBL or ESBL-producing *P. aeruginosa* isolates. Although, ongoing surveillance of these multi-resistant strains is vital in public healthcare settings, allowing for the correct antimicrobial treatment of CF patients and the control of nosocomial infections through the implementation of suitable hygiene regimens.

Independently from the antimicrobial susceptibility, mucoid phenotypes of *P. aeruginosa* in CF respiratory samples represent a non-favorable prognostic aspect.<sup>1,19</sup> In our study, mucoid *P. aeruginosa* isolates were observed in 12% (17 of 146) of the patients and in all age groups, being the highest rate of colonization in the age group > 17 years old. The non-mucoid *P. aeruginosa* isolates exhibited a much higher antimicrobial susceptibility than the mucoid ones.

However, some studies have shown that most patients with *P. aeruginosa* in the airways when clinically stable maintain the same strains of genotypes, when there are episodes of exacerbations.<sup>20</sup>

As caveat in interpreting these results cultures were taken only from patients clinically stable. However, some studies have shown that most patients with *P. aeruginosa* in their airways when clinically stable maintain the same strain genotypes when episodes of exacerbations occur.<sup>20</sup> Therefore, initial antibiotic therapy of an exacerbation of CF is usually

determined by the results of antibiotic susceptibility testing performed on isolates recovered from the most recent culture of that patient.<sup>1</sup>

This study was also limited by the short follow-up period and because the small number of some groups of patients infected with individual strains did not allow for correlating microbiological data to clinical outcomes between groups of patients. Our data emphasize the crucial role of microbiological methods in defining possible therapeutic strategies that may help guiding antibiotic therapy regimens in CF patients. Further research is therefore needed to determine whether the bacteria repertoire in the clinical stable phase is the same during the exacerbation phase.

### ACKNOWLEDGEMENTS

We thank the clinical and laboratory staff of *Hospital Otávio Mangabeira* for their cooperation, and the patients and their families.

### REFERENCES

1. Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. *Respir Care* 2009; 54:595-605.
2. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. *Eur Respir J* 2004; 23:146-58.
3. Saiman L, Siegel J. Infection control in cystic fibrosis. *Clin Microbiol Rev* 2004; 17:57-71.
4. Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. *Semin Respir Infect* 2002; 17:47-56.
5. O'Sullivan BP, Freedman SD. Cystic fibrosis. *Lancet* 2009; 373:1891-904.
6. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. *J Pediatr* 1998; 132:589-95.
7. CLSI. Performance standards for antimicrobial susceptibility testing, in Seventeenth Informational Supplement. 2007, Approved Standard M100-S17: Wayne, PA.
8. Lambiase A, Raia V, Del Pezzo M, Sepe A, Carnovale V, Rosano F. Microbiology of airway disease in a cohort of patients with cystic fibrosis. *BMC Infect Dis* 2006; 6:4.
9. Valenza G, Tappe D, Turnwald D *et al.* Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. *J Cyst Fibros* 2008; 7:123-7.
10. Santana MA, Matos E, do Socorro Fontoura M, Franco R Barreto D, Lemos AC. Prevalence of pathogens in cystic fibrosis patients in Bahia, Brazil. *Braz J Infect Dis*, 2003; 7:69-72.
11. Anzaudo MM, Busquets NP, Ronchi S, Mayoral C. Isolated pathogen microorganisms in respiratory samples from children with cystic fibrosis. *Rev Argent Microbiol* 2005; 37:129-34.
12. García, AD, Ibarra A, Rodríguez FC, Casal M. Antimicrobial susceptibility of bacterial isolates from patients with cystic fibrosis. *Rev Esp Quimioter* 2004; 17:332-5.
13. Razvi S, Quittell L, Sewal A, Quinton H, Marshall B, Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995-2005. *Chest*, 2009.
14. Burns JL, Emerson J, Stapp JR *et al.* Microbiology of sputum from patients at cystic fibrosis centers in the United States. *Clin Infect Dis* 1998; 27:158-63.
15. Nishio H, Komatsu M, Shibata N *et al.* Metallo-beta-lactamase-producing gram-negative bacilli: laboratory-based surveillance in cooperation with 13 clinical laboratories in the Kinki region of Japan. *J Clin Microbiol* 2004; 42:5256-63.
16. Lauretti L, Riccio ML, Mazzarol A *et al.* Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a *Pseudomonas aeruginosa* clinical isolate. *Antimicrob Agents Chemother* 1999; 43:1584-90.
17. Gales AC, Menezes LC, Silbert S, Sader HS. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant *Pseudomonas aeruginosa* producing SPM metallo-beta-lactamase. *J Antimicrob Chemother* 2003; 52:699-702.
18. Gales AC, Menezes LC, Silbert S, Sader HS. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant *Pseudomonas aeruginosa* producing SPM metallo-beta-lactamase. *J Antimicrob Chemother* 2003; 52:699-702.
19. Stewart PS, Rayner J, Roe F, Rees WM. Biofilm penetration and disinfection efficacy of alkaline hypochlorite and chlorosulfamates. *J Appl Microbiol* 2001; 91:525-32.
20. Aaron SD, Ramotar K, Ferris W *et al.* Adult cystic fibrosis exacerbations and new strains of *Pseudomonas aeruginosa*. *Am J Respir Crit Care Med* 2004; 169:811-5.